-+ 0.00%
-+ 0.00%
-+ 0.00%

CARDIOL THERAPEUTICS ACHIEVES PHASE III MAVERIC ENROLLMENT TARGET AHEAD OF SCHEDULE AND EXPANDS PIVOTAL TRIAL TO STRENGTHEN ASSESSMENT OF CARDIOLRX™'S EFFICACY

Reuters·09/23/2026 10:00:01

Please log in to view news